Condition: Bladder (Urothelial, Transitional Cell) Cancer · Non-Muscle Invasive Bladder Carcinoma · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ · Sponsor: Protara Therapeutics
The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older. The main questions it aims to answer are: * Can the study drug help participants with this type of cancer? * Is the study drug safe? * What are the side effects of the study drug? Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.
This description comes directly from the study's public registry record.
Chief R&D Officer · 16468440337 · clinicaltrials@protaratx.com
Always discuss trial participation with your own doctor first.
| East Valley Urology Center of Arizona | Queen Creek, Arizona, United States | Recruiting |
| Arkansas Urology | Little Rock, Arkansas, United States | Recruiting |
| Michael Oefelein Clinical Trials | Bakersfield, California, United States | Recruiting |
| Renown Regional Medical Center | St Louis, Missouri, United States | Recruiting |
| START - Carolinas | Myrtle Beach, South Carolina, United States | Recruiting |
| Arensia Kapitanivka - PPDS | Kapitanivka, Ukraine | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07480356